سعر ازرولانتا 500 مجم فيال 2026

Azithromycin 500 mg vial for injection (1 vial); macrolide antibacterial (New Boston Pharmaceuticals, Egypt).

• Community-acquired pneumonia in patients requiring initial intravenous therapyPopulation: AdultsDailyMed (U.S. National Library of Medicine)
• Pelvic inflammatory disease in patients requiring initial intravenous therapy (add anaerobic cover if anaerobes are suspected)Population: AdultsDailyMed (U.S. National Library of Medicine)

• With IV/oral therapy for community-acquired pneumonia: diarrhoea/loose stools (4.3%), nausea (3.9%), abdominal pain (2.7%), vomiting (1.4%); about 12% had infusion-related reactions, mainly injection-site pain (6.5%) and local inflammation (3.1%).International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• In pelvic inflammatory disease trials: diarrhoea (8.5%), nausea (6.6%), vaginitis (2.8%), abdominal pain, anorexia, rash and pruritus (1.9% each).International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Known hypersensitivity to azithromycin, erythromycin, any macrolide or ketolide.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• History of cholestatic jaundice/hepatic dysfunction associated with prior azithromycin use.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Serious allergic and skin reactions (angioedema, anaphylaxis, AGEP, Stevens-Johnson syndrome, toxic epidermal necrolysis, DRESS), sometimes fatal; hepatotoxicity; infantile hypertrophic pyloric stenosis after neonatal use.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• QT prolongation/torsades de pointes and a possible short-term increase in cardiovascular death; Clostridioides difficile-associated diarrhoea; exacerbation of myasthenia gravis.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Infusion-site reactions: infuse over not less than 60 minutes; concentrations above 2 mg/mL caused local IV-site reactions in all volunteers and should be avoided.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• NelfinavirIncreases azithromycin concentrations; monitor for liver enzyme abnormalities and hearing impairment.DailyMed (U.S. National Library of Medicine)
• Warfarin and other oral anticoagulantsPossible potentiation of anticoagulant effect; monitor prothrombin time carefully.DailyMed (U.S. National Library of Medicine)
• Digoxin, colchicine, phenytoinInteractions seen with other macrolides; careful monitoring is advised.DailyMed (U.S. National Library of Medicine)

• Published literature and decades of postmarketing experience have not identified drug-associated risks of major birth defects, miscarriage or adverse maternal or fetal outcomes.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Azithromycin is present in human milk (persisting up to 48 hours after a 500 mg IV dose); monitor the breastfed infant for diarrhoea, vomiting or rash.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Azithromycin: Binds the 50S ribosomal subunit of susceptible bacteria and inhibits bacterial protein synthesis.